RESPIRATORY SYNCYTIAL VIRUS (RSV)

RSV is frequently associated with the risk it brings to young children, but the virus also poses a high risk for adults with pre-existing health conditions and older adults. Hospitalization rates due to RSV in people with chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), coronary artery disease (CAD), asthma, and diabetes have been found to be higher than the rates in patients without these conditions.

This study aims to evaluate the safety and immune response of an investigational vaccine (mRNA-1345) aimed at preventing RSV infection in high risk adults.

Key Study Information:

  • Treatment Area:

    Respiratory Syncytial Virus (RSV)

  • Trial Site Locations:
    Fylde Coast Clinical Research Blackpool, Royal Devon University Healthcare NHS Foundation Trust, Royal Free Hospital London
  • Study Type:

    Interventional

  • Study Aim:

    To evaluate the safety and immune response of an investigational vaccine (mRNA-1345) aimed at preventing RSV infection in high risk adults

  • Recruitment Target:

    100 patients

  • Details of practice revenue available on request.
Join this study Right Arrow

Speak to our study support specialist for more information on this study.

10 minutes to participate in this study

  • 1
  • 2
  • 3
  • 4

Step One

Practice - Select a study

uMed supports multiple studies sponsored by commercial and academic institutions.

Your practice can choose a study via our website or dedicated web application.

Step Two

Practice - Review & Approve Eligible Patients

uMed runs a study specific search to identify potential participants.

uMed searches are compatible with EMIS or SystmOne. The results of this search are available to your practice in our web application for sign-off.

Previous

Step Three

uMed - Patient Contact

Once approved, we manage patient contact on your behalf via SMS, email and/or letter.

We provide a dedicated study support line for all patient enquiries to minimise incoming calls to your practice.

For most studies, between 10-30% of patients engage with our outreach.

Previous

Step Four

Patient - Consents to Join Study

Congratulations! You've empowered your patients to participate in vital clinical research that is most relevant for them.

Once the study concludes, we will share results and patient feedback with you so that you can see the impact of your participation. Any revenue generated from commercial studies is shared with your practice.

Previous

Not yet registered with uMed? Join over 400 GP Practices across the UK within the uMed Research Network and take part in the RESPIRATORY SYNCYTIAL VIRUS (RSV) study. Join the uMed Research Network.

More about RESPIRATORY SYNCYTIAL VIRUS (RSV)

Who can join this study?
Participants must meet one of the following criteria to be eligible to participate:

  • Be 18 years of age or older
  • Be diagnosed with at least one of the following: Coronary artery disease (CAD) or congestive heart failure (CHF), Chronic lung disease (COPD, asthma, or other,) Stable type 1 or type 2 diabetes, controlled with medication
  • Not be pregnant or planning on becoming pregnant for at least 3 months following your vaccine visit

What Vaccine Will Be Given?
All participants will receive the investigational vaccine, mRNA-1345. Participants aged 18 to 59 years will be randomly assigned to a certain dose. Participants aged 60 years and older will all receive the same dose to allow for comparison.

Register your interest in this study

 

Fill in the below form and a member of our team will be in touch to discuss next steps to participate in this study.

    Study name

    Practice name

    Your name

    Your role

    Email

    Phone number